190 related articles for article (PubMed ID: 34821881)
1. Naxitamab: a humanized anti-glycolipid disialoganglioside (anti-GD2) monoclonal antibody for treatment of neuroblastoma.
Slatnick LR; Jimeno A; Gore L; Macy ME
Drugs Today (Barc); 2021 Nov; 57(11):677-688. PubMed ID: 34821881
[TBL] [Abstract][Full Text] [Related]
2. Naxitamab: First Approval.
Markham A
Drugs; 2021 Feb; 81(2):291-296. PubMed ID: 33616889
[TBL] [Abstract][Full Text] [Related]
3. How we approach the treatment of patients with high-risk neuroblastoma with naxitamab: experience from the Hospital Sant Joan de Déu in Barcelona, Spain.
Castañeda A; Gorostegui M; Miralles SL; Chamizo A; Patiño SC; Flores MA; Garraus M; Lazaro JJ; Santa-Maria V; Varo A; Muñoz JP; Mora J
ESMO Open; 2022 Apr; 7(2):100462. PubMed ID: 35397431
[TBL] [Abstract][Full Text] [Related]
4. Naxitamab combined with granulocyte-macrophage colony-stimulating factor as consolidation for high-risk neuroblastoma patients in complete remission.
Mora J; Castañeda A; Gorostegui M; Santa-María V; Garraus M; Muñoz JP; Varo A; Perez-Jaume S; Mañe S
Pediatr Blood Cancer; 2021 Oct; 68(10):e29121. PubMed ID: 34022112
[TBL] [Abstract][Full Text] [Related]
5. GM-CSF, G-CSF or no cytokine therapy with anti-GD2 immunotherapy for high-risk neuroblastoma.
Mora J; Modak S; Kinsey J; Ragsdale CE; Lazarus HM
Int J Cancer; 2024 Apr; 154(8):1340-1364. PubMed ID: 38108214
[TBL] [Abstract][Full Text] [Related]
6. Guidelines for outpatient administration of naxitamab: Experience from Atrium Health Levine Children's Hospital.
Trovillion EM; Michael M; Jordan CC; Brown L; Phillips K; Oesterheld J; Saulnier-Sholler G
Cancer Med; 2024 Feb; 13(3):e7045. PubMed ID: 38396377
[TBL] [Abstract][Full Text] [Related]
7. Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.
Parsons K; Bernhardt B; Strickland B
Ann Pharmacother; 2013 Feb; 47(2):210-8. PubMed ID: 23386066
[TBL] [Abstract][Full Text] [Related]
8. Humanized 3F8 Anti-GD2 Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma: A Phase 1 Clinical Trial.
Kushner BH; Cheung IY; Modak S; Basu EM; Roberts SS; Cheung NK
JAMA Oncol; 2018 Dec; 4(12):1729-1735. PubMed ID: 30326045
[TBL] [Abstract][Full Text] [Related]
9. Outpatient administration of naxitamab in combination with granulocyte-macrophage colony-stimulating factor in patients with refractory and/or relapsed high-risk neuroblastoma: Management of adverse events.
Mora J; Chan GC; Morgenstern DA; Nysom K; Bear MK; Tornøe K; Kushner BH
Cancer Rep (Hoboken); 2023 Jan; 6(1):e1627. PubMed ID: 35579862
[TBL] [Abstract][Full Text] [Related]
10. Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes.
Muñoz JP; Larrosa C; Chamorro S; Perez-Jaume S; Simao M; Sanchez-Sierra N; Varo A; Gorostegui M; Castañeda A; Garraus M; Lopez-Miralles S; Mora J
Cancers (Basel); 2023 Oct; 15(19):. PubMed ID: 37835531
[TBL] [Abstract][Full Text] [Related]
11. Partial Response to Naxitamab for Brain Metastasis in Neuroblastoma.
Onyeukwu C; Williams A; Seyboth B; Muñoz L; Scaria G; Kent P
J Pediatr Hematol Oncol; 2024 Mar; 46(2):e188-e190. PubMed ID: 38189408
[TBL] [Abstract][Full Text] [Related]
12. Anti-disialoganglioside antibody internalization by neuroblastoma cells as a mechanism of immunotherapy resistance.
Tibbetts R; Yeo KK; Muthugounder S; Lee MH; Jung C; Porras-Corredor T; Sheard MA; Asgharzadeh S
Cancer Immunol Immunother; 2022 Jan; 71(1):153-164. PubMed ID: 34043024
[TBL] [Abstract][Full Text] [Related]
13. Multidisciplinary Clinical Care in the Management of Patients Receiving Anti-GD2 Immunotherapy for High-Risk Neuroblastoma.
Cabral J; Fernandez EI; Toy B; Secola R
Paediatr Drugs; 2023 Jan; 25(1):13-25. PubMed ID: 36434427
[TBL] [Abstract][Full Text] [Related]
14. Naxitamab Activity in Neuroblastoma Cells Is Enhanced by Nanofenretinide and Nanospermidine.
Galassi L; Rossi M; Lodeserto P; Lenzi M; Borsetti F; Voltattorni M; Farruggia G; Blasi P; Orienti I
Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36839972
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy with anti-G
Kushner BH; Modak S; Kramer K; Basu EM; Iglesias-Cardenas F; Roberts SS; Cheung NV
Int J Cancer; 2023 Jan; 152(2):259-266. PubMed ID: 35913764
[TBL] [Abstract][Full Text] [Related]
16. Pain mitigation and management strategies for anti-GD2 infusions: An expert consensus.
Nysom K; Morad AG; Rafael MS; Zier J; Marachelian A; Watt T; Morgenstern DA
Pediatr Blood Cancer; 2023 May; 70(5):e30217. PubMed ID: 36772891
[TBL] [Abstract][Full Text] [Related]
17. Dinutuximab: An Anti-GD2 Monoclonal Antibody for High-Risk Neuroblastoma.
Ploessl C; Pan A; Maples KT; Lowe DK
Ann Pharmacother; 2016 May; 50(5):416-22. PubMed ID: 26917818
[TBL] [Abstract][Full Text] [Related]
18. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.
Yu AL; Gilman AL; Ozkaynak MF; London WB; Kreissman SG; Chen HX; Smith M; Anderson B; Villablanca JG; Matthay KK; Shimada H; Grupp SA; Seeger R; Reynolds CP; Buxton A; Reisfeld RA; Gillies SD; Cohn SL; Maris JM; Sondel PM;
N Engl J Med; 2010 Sep; 363(14):1324-34. PubMed ID: 20879881
[TBL] [Abstract][Full Text] [Related]
19. A transplantable TH-MYCN transgenic tumor model in C57Bl/6 mice for preclinical immunological studies in neuroblastoma.
Kroesen M; Nierkens S; Ansems M; Wassink M; Orentas RJ; Boon L; den Brok MH; Hoogerbrugge PM; Adema GJ
Int J Cancer; 2014 Mar; 134(6):1335-45. PubMed ID: 24038106
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]